Astrazeneca plc
Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - General
AstraZeneca (LSE/STO/Nasdaq: AZN ) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.
Did you know?
Pays a 1.73% dividend yield.
Current Price
$184.74
-1.40%GoodMoat Value
$228.37
23.6% undervaluedProfile
Valuation (TTM)
Market Cap$286.51B
P/E27.58
EV—
P/B5.89
Shares Out1.55B
P/Sales4.74
Revenue$60.44B
EV/EBITDA15.28
Astrazeneca plc (AZN) Stock Analysis
Market Cap$286.51B
Current Price$184.74
P/E Ratio27.58
Forward P/E—
PEG Ratio4.71
EPS$6.54
Book Value$31.38
P/B Ratio5.89
AZN Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use 34.1% FCF growth (CAGR)
Cash vs Debt
Net Debt: 23.9B
Revenue
24.4B
FY19
26.6B
FY20
37.4B
FY21
44.4B
FY22
45.8B
FY23
54.1B
FY24
58.7B
FY25
Net Income
1.3B
FY19
3.2B
FY20
112M
FY21
3.3B
FY22
6.0B
FY23
7.0B
FY24
10.2B
FY25
AZN 52-Week Range
$128.84
$208.45
50-Day MA: $196.03200-Day MA: $174.35
Did you know?
Profit margin stands at 17.2%.
Astrazeneca plc (AZN) Financial Summary
Astrazeneca plc (AZN) is a Healthcare company in the Drug Manufacturers - General industry, listed on NASDAQ. The stock currently trades at $184.74 with a market capitalization of $286.51B.
Key valuation metrics include a P/E ratio of 27.58, price-to-book ratio of 5.89, and EPS of $6.54. The company reports a profit margin of 17.2% and return on equity of 21.3%.
AZN Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $286.51B |
| P/E Ratio | 27.58 |
| EPS | $6.54 |
| P/B Ratio | 5.89 |
| P/S Ratio | 4.74 |
| EV/EBITDA | 15.28 |
| Dividend Yield | 1.73% |
| Profit Margin | 17.2% |
| Return on Equity | 21.3% |
| Debt/Equity | 0.61 |
AZN Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $24.38B | $1.33B |
| FY20 | $26.62B | $3.20B |
| FY21 | $37.42B | $112.00M |
| FY22 | $44.35B | $3.29B |
| FY23 | $45.81B | $5.96B |
| FY24 | $54.07B | $7.04B |
| FY25 | $58.74B | $10.22B |
Astrazeneca plc (AZN) Valuation
Based on GoodMoat's DCF model, Astrazeneca plc has a fair value estimate of $228.37. At the current price of $184.74, the stock appears 19.1% undervalued relative to our intrinsic value estimate.
AZN Quality Indicators
Astrazeneca plc maintains a profit margin of 17.2% and an operating margin of 23.4%. Return on equity stands at 21.3%. The current ratio is 0.94. Debt-to-equity ratio is 0.61.
About Astrazeneca plc
AstraZeneca (LSE/STO/Nasdaq: AZN ) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.
AZN Free Cash Flow
Astrazeneca plc generated $11.78B in trailing twelve-month free cash flow, representing an FCF yield of 4.11%. This moderate FCF yield indicates reasonable cash generation.
AZN Shares Outstanding
Astrazeneca plc has 1.55 billion shares outstanding at a share price of $184.74, giving it a market capitalization of $286.51B.